Assessment of Treatment-Resistant Schizophrenia

Defining Treatment Resistance

The American Psychiatric Association defines treatment-resistant schizophrenia as requiring at least two failed trials of different antipsychotics, with clozapine being the definitive first-line treatment for confirmed cases 1, 2
Treatment resistance is characterized by moderate to severe symptoms persisting despite treatment, measured by standardized scales, such as the Positive and Negative Syndrome Scale (PANSS) or the Brief Psychiatric Rating Scale (BPRS) 1, 3
At least 2 different antipsychotics from different classes must be tried, with each trial lasting ≥6 weeks at therapeutic doses equivalent to ≥1000 mg/day chlorpromazine or mid-range dosing for the specific agent 1, 2, 4
Functional impairment, with at least moderate impairment in daily functioning, is also a criterion for treatment-resistant schizophrenia 1, 3
Adherence verification, with ≥80% medication adherence confirmed by at least two methods, plus antipsychotic blood levels on at least one occasion, is necessary to rule out non-adherence as a cause of treatment resistance 5

The American Psychiatric Association recommends clozapine as the gold standard and only FDA-approved treatment for treatment-resistant schizophrenia, with superior efficacy compared to all other antipsychotics 2, 3
Clozapine initiation should start at 12.5 mg once or twice daily, with increases by 25-50 mg/day if tolerated, and a target dose of 300-450 mg/day by the end of week 2 3
An adequate clozapine trial requires therapeutic blood levels ≥350 ng/mL on at least two occasions, a minimum dose of 500 mg/day, and a duration of at least 3 months after achieving therapeutic plasma levels 3, 5

Augmentation with a partial D2 agonist, such as aripiprazole, may reduce clozapine dose requirements and side effects while addressing residual symptoms 6
Augmentation with a second antipsychotic, a D2 antagonist, may be considered, although evidence is limited 6
Adjunctive treatments, such as antidepressants or mood stabilizers, may be used to target specific symptom domains 3

Clozapine has FDA-approved indications for suicide risk reduction in patients with schizophrenia or schizoaffective disorder at chronic risk for suicidal behavior 2
Clozapine may be considered for patients with substantial risk of aggressive behavior despite other treatments 2

Premature clozapine discontinuation should be avoided, ensuring adequate trial duration and dosing before declaring failure 3, 5
Subtherapeutic dosing should be avoided, with verification of blood levels ≥350 ng/mL 3, 5
Non-adherence should be ruled out with blood levels before diagnosing treatment resistance 3, 5
Inadequate trial duration should be avoided, with each antipsychotic trial lasting ≥6 weeks at therapeutic doses before moving to the next agent 1, 4

The American Psychiatric Association recommends considering augmentation with a second antipsychotic, such as aripiprazole or risperidone, to clozapine for persistent symptoms, with limited evidence supporting this approach 7, 8

Paliperidone may be considered for augmentation of clozapine in patients with persistent negative symptoms, based on limited case series evidence 8